Mei-Ling Cheng1, Chao-Hung Wang2, Ming-Shi Shiao1, Min-Hui Liu3, Yu-Yen Huang4, Cheng-Yu Huang5, Chun-Tai Mao4, Jui-Fen Lin5, Hung-Yao Ho6, Ning-I Yang4. 1. Healthy Aging Research Center, Chang Gung University, Tao-Yuan, Taiwan; Metabolomics Core Laboratory, Chang Gung University, Tao-Yuan, Taiwan; Department of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan. 2. Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, and Chang Gung University College of Medicine, Taoyuan, Taiwan. Electronic address: bearty54@gmail.com. 3. Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, and Chang Gung University College of Medicine, Taoyuan, Taiwan; Department of Nursing, National Yang-Ming University, Taipei, Taiwan. 4. Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, and Chang Gung University College of Medicine, Taoyuan, Taiwan. 5. Healthy Aging Research Center, Chang Gung University, Tao-Yuan, Taiwan. 6. Healthy Aging Research Center, Chang Gung University, Tao-Yuan, Taiwan; Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Tao-Yuan, Taiwan.
Abstract
BACKGROUND: Identification of novel biomarkers is needed to improve the diagnosis and prognosis of heart failure (HF). Metabolic disturbance is remarkable in patients with HF. OBJECTIVES: This study sought to assess the diagnostic and prognostic values of metabolomics in HF. METHODS: Mass spectrometry-based profiling of plasma metabolites was performed in 515 participants; the discovery phase study enrolled 51 normal control subjects and 183 HF patients, and the validation study enrolled 63 control subjects and 218 patients with stage C HF. Another independent group of 32 patients with stage C HF who recovered to New York Heart Association functional class I at 6 and 12 months was profiled as the "recovery" group. RESULTS: A panel of metabolites, including histidine, phenylalanine, spermidine, and phosphatidylcholine C34:4, has a diagnostic value similar to B-type natriuretic peptide (BNP). In the recovery group, the values of this panel significantly improved at 6 and 12 months. To evaluate the prognostic values, events were defined as the combined endpoints of death or HF-related re-hospitalization. A metabolite panel, which consisted of the asymmetric methylarginine/arginine ratio, butyrylcarnitine, spermidine, and the total amount of essential amino acids, provided significant prognostic values (p < 0.0001) independent of BNP and traditional risk factors. The prognostic value of the metabolite panel was better than that of BNP (area under the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95). These findings were corroborated in the validation study. CONCLUSIONS: Metabolomics demonstrate powerful diagnostic value in estimating HF-related metabolic disturbance. The profile of metabolites provides better prognostic value versus conventional biomarkers.
BACKGROUND: Identification of novel biomarkers is needed to improve the diagnosis and prognosis of heart failure (HF). Metabolic disturbance is remarkable in patients with HF. OBJECTIVES: This study sought to assess the diagnostic and prognostic values of metabolomics in HF. METHODS: Mass spectrometry-based profiling of plasma metabolites was performed in 515 participants; the discovery phase study enrolled 51 normal control subjects and 183 HF patients, and the validation study enrolled 63 control subjects and 218 patients with stage C HF. Another independent group of 32 patients with stage C HF who recovered to New York Heart Association functional class I at 6 and 12 months was profiled as the "recovery" group. RESULTS: A panel of metabolites, including histidine, phenylalanine, spermidine, and phosphatidylcholine C34:4, has a diagnostic value similar to B-type natriuretic peptide (BNP). In the recovery group, the values of this panel significantly improved at 6 and 12 months. To evaluate the prognostic values, events were defined as the combined endpoints of death or HF-related re-hospitalization. A metabolite panel, which consisted of the asymmetric methylarginine/arginine ratio, butyrylcarnitine, spermidine, and the total amount of essential amino acids, provided significant prognostic values (p < 0.0001) independent of BNP and traditional risk factors. The prognostic value of the metabolite panel was better than that of BNP (area under the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95). These findings were corroborated in the validation study. CONCLUSIONS: Metabolomics demonstrate powerful diagnostic value in estimating HF-related metabolic disturbance. The profile of metabolites provides better prognostic value versus conventional biomarkers.
Authors: M Dan McKirnan; Yasuhiro Ichikawa; Zheng Zhang; Alice E Zemljic-Harpf; Sili Fan; Dinesh Kumar Barupal; Hemal H Patel; H Kirk Hammond; David M Roth Journal: Life Sci Date: 2019-02-05 Impact factor: 5.037
Authors: David E Lanfear; Joseph J Gibbs; Jia Li; Ruicong She; Christopher Petucci; Jeffrey A Culver; W H Wilson Tang; Yigal M Pinto; L Keoki Williams; Hani N Sabbah; Stephen J Gardell Journal: JACC Heart Fail Date: 2017-11 Impact factor: 12.035
Authors: Robert W McGarrah; Scott B Crown; Guo-Fang Zhang; Svati H Shah; Christopher B Newgard Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Yiyi Zhang; Elena Blasco-Colmenares; Amy C Harms; Barry London; Indrani Halder; Madhurmeet Singh; Samuel C Dudley; Rebecca Gutmann; Eliseo Guallar; Thomas Hankemeier; Gordon F Tomaselli; Alan Cheng Journal: Europace Date: 2015-10-25 Impact factor: 5.214
Authors: Tariq Ahmad; Jacob P Kelly; Robert W McGarrah; Anne S Hellkamp; Mona Fiuzat; Jeffrey M Testani; Teresa S Wang; Amanda Verma; Marc D Samsky; Mark P Donahue; Olga R Ilkayeva; Dawn E Bowles; Chetan B Patel; Carmelo A Milano; Joseph G Rogers; G Michael Felker; Christopher M O'Connor; Svati H Shah; William E Kraus Journal: J Am Coll Cardiol Date: 2016-01-26 Impact factor: 24.094